Palbociclib (PAL) + cetuximab (CET) vs CET in patients (pts) with head and neck cancer: Asian subgroup analysis

Makoto Tahara(National Cancer Center Hospital East), Douglas Adkins(Washington University in St. Louis), Justin Hoffman(Pfizer (United States)), Bohuslav Melichar(Palacký University Olomouc), Shaw Ling Wang(Pfizer (United States)), Assuntina G. Sacco(University of California San Diego), Kenneth A. Kern(Pfizer (United States)), Qi Shen(Qingdao University), Peter Oppelt(Washington University in St. Louis), Jean Francois Martini(Pfizer (United States)), Holger Thurm(Pfizer (United States)), Jin Lin(National Yang Ming Chiao Tung University), Jessica Ley(Washington University in St. Louis)
Annals of Oncology
October 1, 2019
10.1093/annonc/mdz338.056
Cited by 0

Related Papers

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2020|1.1k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618